Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 12 Oct 2026, 14:23 UTC. The headline in use is “Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary…”. This note is SignalsMonitor's own briefing, not the publisher's article.